Krishna Institute of Medical Sciences Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Abhinay Bollineni

Algemeen directeur

₹22.0m

Totale compensatie

Percentage CEO-salaris	77.3%
Dienstverband CEO	5.3yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Abhinay Bollineni's beloning veranderd ten opzichte van Krishna Institute of Medical Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹3b
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹22m	₹17m	₹3b
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹20m	₹15m	₹3b
Dec 31 2022	n/a	n/a	₹3b
Sep 30 2022	n/a	n/a	₹3b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹12m	₹12m	₹3b
Dec 31 2021	n/a	n/a	₹3b
Sep 30 2021	n/a	n/a	₹3b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹9m	₹9m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Mar 31 2020	₹8m	₹8m	₹1b
Mar 31 2019	₹5m	₹5m	-₹477m

Compensatie versus markt: De totale vergoeding ($USD 260.55K ) Abhinay } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 590.37K ).

Compensatie versus inkomsten: De vergoeding van Abhinay is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Abhinay Bollineni (36 yo)

5.3yrs

Tenure

₹22,000,000

Compensatie

Dr. Abhinay Bollineni serves as Chief Executive Officer of Krishna Institute of Medical Sciences Limited since July 3, 2019 and has been its Executive Director since January 18, 2019. He holds a bachelor’s...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bhaskara Bollineni	Founder	no data	₹38.67m	32.25% ₹ 76.8b
Abhinay Bollineni	CEO & Executive Director	5.8yrs	₹22.00m	0.069% ₹ 164.1m
Anitha Dandamudi	Director of Operations & Wholetime Director	no data	₹5.80m	geen gegevens
Saumen Chakraborty	Independent Director	no data	₹3.52m	geen gegevens
Yalamanchili Rani	Additional Non-Executive & Independent Director	2.5yrs	₹1.06m	geen gegevens
Venkata Jasthi	Independent Director	no data	₹1.06m	geen gegevens
Adwik Bollineni	Additional Non-Executive Non-Independent Director	less than a year	geen gegevens	0.010% ₹ 24.2m
Ratna Kaza	Independent Director	no data	₹1.06m	geen gegevens

2.5yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 543308 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Krishna Institute of Medical Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 29, 2024

Krishna Institute of Medical Sciences Limited Announces Cessation of Rajeswara Rao Gandu as Independent Director

Krishna Institute of Medical Sciences Limited Announces Ceasation of Pankaj Vaish as Independent Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Announces Resignation of Shantanu Rastogi as Non-Executive & Non-Independent Director

Recent updates

Price target increased by 9.8% to ₹546

Second quarter 2025 earnings released: EPS: ₹2.68 (vs ₹2.30 in 2Q 2024)

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.24% stake in KIMS-SUNSHINE Hospitals for approximately INR 400 million.

Krishna Institute of Medical Sciences Limited to Report Q2, 2025 Results on Nov 09, 2024

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.21% stake in KIMS-SUNSHINE Hospitals for approximately INR 365.16 million.

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) Completed the acquisition of Chalasani Hospitals Private Limited.

Price target increased by 7.1% to ₹2,419

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q1, 2025 Results on Aug 07, 2024

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) entered into agreement to acquire Chalasani Hospitals Private Limited for INR 750 million.

Full year 2024 earnings: EPS and revenues miss analyst expectations

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 29, 2024

Krishna Institute of Medical Sciences Limited to Report Q4, 2024 Results on May 16, 2024

Price target increased by 8.3% to ₹2,327

New minor risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Krishna Institute of Medical Sciences Limited Announces Cessation of Rajeswara Rao Gandu as Independent Director

Krishna Institute of Medical Sciences Limited to Report Q3, 2024 Results on Feb 03, 2024

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired 5.04% stake in KIMS-SUNSHINE Hospitals for INR 740 million.

Krishna Institute of Medical Sciences Limited Announces Ceasation of Pankaj Vaish as Independent Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Appoints Adwik Bollineni as Additional Director

Krishna Institute of Medical Sciences Limited Announces Resignation of Shantanu Rastogi as Non-Executive & Non-Independent Director

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 6.86% in Spanv Medisearch Lifesciences Private Limited

Krishna Institute of Medical Sciences Limited to Report Q2, 2024 Results on Nov 07, 2023

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 5.72% stake in Spanv Medisearch Lifesciences Private Limited for approximately INR 222 million.

Price target increased by 8.0% to ₹2,099

Price target increased by 8.6% to ₹1,826

Full year 2023 earnings: EPS exceeds analyst expectations

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.49% stake in Sarvejana Healthcare Private Limited for INR 350 million.

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired an additional 2.49% stake in Sarvejana Healthcare Private Limited for INR 350 million.

Krishna Institute of Medical Sciences Limited to Report Q1, 2024 Results on Aug 07, 2023

Krishna Institute of Medical Sciences Limited Appoints Mr. Sachin Ashok Salvi as the Chief Financial Officer, Effect from August 01, 2023

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 30, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q4, 2023 Results on May 18, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Krishna Institute of Medical Sciences Limited to Report Q3, 2023 Results on Feb 09, 2023

Krishna Institute of Medical Sciences Limited (NSEI:KIMS) acquired additional 5.53% stake in Sarvejana Healthcare Private Limited.

Krishna Institute of Medical Sciences Limited Announces Resignation of Mr. Shantanu Rastogi as Director (Non-Executive)

Krishna Institute of Medical Sciences Limited (BSE:543308) acquired 4.07% stake in KIMS Hospital Enterprises Private Ltd for INR 245 million.

Krishna Institute of Medical Sciences Limited (BSE:543308) acquired additional 7.79% stake in Arunodaya Hospitals Private Limited.

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q2, 2023 Results on Nov 11, 2022

Price target increased to ₹1,509

Krishna Institute of Medical Sciences Limited (BSE:543308) acquired majority stake 51% Spanv Medisearch Lifesciences Private Limited.

Krishna Institute of Medical Sciences Limited (BSE:543308) agreed to acquire 51% Spanv Medisearch Lifesciences Private Limited.

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Krishna Institute of Medical Sciences Limited (BSE:543308) agreed to acquire 51% stake in KIMS Manavata Hospital.

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Krishna Institute of Medical Sciences Limited, Annual General Meeting, Aug 11, 2022

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Krishna Institute of Medical Sciences Limited to Report Q3, 2022 Results on Feb 10, 2022

Insufficient new directors

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹11.48 (vs ₹3.85 in 1Q 2021)

Investor Director Sandeep Naik has left the company

Investor sentiment improved over the past week

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd